Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

计划入组 138 人 · 首次发布于 2026 年 1 月 22 日

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

计划入组 138 人 · 首次发布于 2025 年 12 月 31 日

Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma

计划入组 39 人 · 首次发布于 2003 年 1 月 27 日

Exatecan

C₂₄H₂₂FN₃O₄

Exatecan mesilate

V66-Exatecan

Promatix Biosciences Awarded Innovate UK Grant to Advance First-in-Class EGFR × EphA2 Cis-Bispecific ADC

Promatix Biosciences Reports 50-Fold Potency Improvement with Novel Bispecific ADC for Colorectal Cancer

Innate Pharma Completes Enrollment in Phase 1 Dose Escalation of IPH4502, a Novel Nectin-4 Exatecan ADC, with Preliminary Data Expected by Year-End